Literature DB >> 9217182

Distribution of T-cell signalling molecules in human myeloma.

A Bianchi1, S Mariani, E Beggiato, P Borrione, S Peola, M Boccadoro, A Pileri, M Massaia.   

Abstract

It is controversial whether altered levels of TCR/CD3-associated signalling molecules play a role in the T-cell dysfunction of cancer patients. In multiple myeloma (MM), peripheral blood T (PBT) lymphocytes are functionally impaired by prolonged exposure to tumour cells, and so we investigated the organization of the TCR/CD3-associated signal transduction machinery. The aim of this study was two-fold: first, to investigate the levels of CD3zeta, p56(lck), p59(fyn), ZAP-70, protein kinase C-alpha (PKC-alpha) and phospholipase C-gamma (PLC-gamma) in MM PBT cells; second, to determine whether levels of expression were correlated with clinical or prognostic factors. Forty-four MM patients were studied and 25 age-matched normal donors served as controls. On average, PKC-alpha was the only significantly decreased (P<0.001) signalling molecule, whereas levels of CD3zeta, p56(lck), p59(fyn), PLC-gamma and ZAP-70 were not statistically different. However, there was wide variation between individual patients, and levels for each single protein also varied. A 75% or greater decrease in protein expression was observed, ranging from 8% (p59(fyn)) to 68% (PCK-alpha) of MM patients. When patients were grouped according to the cut-off values of prognostic factors such as the serum levels of C reactive protein (CRP), beta2-microglobulin (beta2M), neopterin (NPT) and the labelling index (LI%) of bone marrow (BM) plasma cells, the only difference observed was the lower PKC-alpha expression in patients with high serum NPT values. None of the T-cell signalling molecule levels was affected by the duration of tumour exposure, calculated on the number of years and/or months that had elapsed since diagnosis, or by disease status. In conclusion, there was a significant decrease of PCK-alpha in MM T cells; however, neither this decrease nor the heterogenous levels of the other T-cell signalling molecules were clearly correlated with prognosis, duration of tumour exposure, and disease status.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9217182     DOI: 10.1046/j.1365-2141.1997.1482961.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.

Authors:  Güllü Görgün; Elisabetta Calabrese; Ender Soydan; Teru Hideshima; Giulia Perrone; Madhavi Bandi; Diana Cirstea; Loredana Santo; Yiguo Hu; Yu-Tzu Tai; Sabikun Nahar; Naoya Mimura; Claire Fabre; Noopur Raje; Nikhil Munshi; Paul Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2010-07-22       Impact factor: 22.113

2.  Primarily screening and analyzing ESTs differentially expressed in rats' primary liver cancer.

Authors:  Dandan Liu; Lijuan Zhi; Mingxia Ma; Dan Qiao; Meijuan Wang; Yawei Wang; Baijie Jin; Anqi Li; Guting Liu; Yiqing Zhang; Yanyan Song; Hongxu Zhang
Journal:  Chin J Cancer Res       Date:  2013-02       Impact factor: 5.087

3.  Variations in suppressor molecule ctla-4 gene are related to susceptibility to multiple myeloma in a polish population.

Authors:  Lidia Karabon; Edyta Pawlak-Adamska; Anna Tomkiewicz; Anna Jedynak; Marek Kielbinski; Dariusz Woszczyk; Stanisław Potoczek; Anna Jonkisz; Kazimierz Kuliczkowski; Irena Frydecka
Journal:  Pathol Oncol Res       Date:  2011-07-09       Impact factor: 3.201

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.